Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIM STUDY
NCT06987513Phase 2Completed
- Sponsor
- Altimmune, Inc.
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing Pemvidutide 2.4 mg with Placebo (2 arms). Primary endpoint: Change from baseline in the average number of heavy drinking days per week. Started May 2025; status: completed.
02
Drugs
pemvidutide
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06987513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987513.